Broad-based growth in radiopharmaceuticals and contrast products propelled Covidien's Imaging Solutions business unit to an 18% increase in sales in its fiscal third quarter.
For the period (end-June 30), the division of the Hamilton, Bermuda-based firm had sales of $319 million, up from $271 million in the fiscal third quarter of last year. Covidien does not provide specific earnings figures for each business unit.
In quarterly highlights, both radiopharmaceuticals and contrast products grew at a strong double-digit pace, according to Covidien. Growth in radiopharmaceuticals was paced by good performance in the U.S., while higher contrast product volumes in Europe, Asia, and Latin America more than offset pricing pressure in the U.S., Covidien said.
Related Reading
Covidien posts strong Q2, May 7, 2008
Covidien gets tentative nod for generic sestamibi, February 27, 2008
Covidien settles Medrad litigation, February 14, 2008
NRC investigates Covidien production issue, February 8, 2008
Medical sales drive Covidien's Q1 growth, February 7, 2008
Copyright © 2008 AuntMinnie.com
